Literature DB >> 1477306

Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study.

A F Oberholzer1, C Hendriksen, A U Monsch, B Heierli, H B Stähelin.   

Abstract

The short- and long-term treatment tolerance of low-dose clozapine was retrospectively investigated in 18 psychogeriatric patients. Discontinued use of the drug because of side effects or inefficiency was required for only four patients. In the long-term treatment group leukopenia was not observed, and disturbances of liver function appeared to be very infrequent. A second group of seven severely demented psychogeriatric inpatients who were currently being treated with low-dose clozapine underwent a withdrawal study in order to evaluate the therapeutic efficacy of the drug, measured by the NOSIE and the SCAG scales. The results indicate that for patients such as these, with paranoid or socially disturbing behavior who also tend to develop severe neurological side effects with classical neuroleptics, a low-dose administration of clozapine is an acceptable alternative treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477306     DOI: 10.1017/s1041610292001017

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  10 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 4.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 5.  Psychotropic drugs, aging and community care.

Authors:  M Philpot; A Puranik
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

6.  Low doses of clozapine may stabilize treatment-resistant bipolar patients.

Authors:  Bettina S Fehr; M Erkan Ozcan; Trisha Suppes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 7.  Treatment of schizophrenia and delusional disorder in the elderly.

Authors:  J H Eastham; D V Jeste
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

8.  Treatment of severe borderline personality disorder with clozapine.

Authors:  Adarsh Kumar Vohra
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

9.  Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Yura Choi; Ha Jin Jeong; Quan Feng Liu; Seung Tack Oh; Byung-Soo Koo; Yeni Kim; In-Won Chung; Yong Sik Kim; Songhee Jeon
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

10.  Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review.

Authors:  Christos G Theleritis; Kostas T Siarkos; Antonios M Politis
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.